March 30, 2021
Neosinus enters into Channel Partnership Agreement with US ENT Partners to Expand Market Access for their Revolutionary Intranasal Delivery Device
RALEIGH, February 8, 2021 /PUBLIC RELEASE/ -- Neosinus Health, an emerging Drug Development Platform Company, which has developed a best-in-class configurable intranasal delivery platform has partnered with US ENT Partners to expand market access across North America to accelerate marketing and distribution of their novel Nasal Rinse Device.
As part of the agreement, Neosinus will join the ranks of top medical device and healthcare product companies that have partnered with US ENT to improve market access for providers and patients that will benefit from best-in-class products and services. As a leading GPO for Ear, Nose, and Throat (ENT) clinical practices across North America, US ENT has developed a product and services procurement platform with access to thousands of ENT providers and their local, specialty, and compounding pharmacies.
The partnership accelerates access to the expanding Neosinus line of consumer products, starting with their novel Nasal Rinse Device, which was developed for the treatment of Sinus Pressure, Allergies, Nasal Congestion, and to improve overall Sinus Health. As demonstrated by market feedback since the recent launch of the Neosinus Rinse Kit, the device delivers a targeted rinse experience like no other product on the market, so the expanded market access will be a win for patients and healthcare providers.
New Design and Rinse Experience: Unlike any other intranasal delivery product on the market, the device is designed based on the anatomy of the nose. It features a curved nozzle with directional control for a targeted rinse experience. This allows the device to bypass nasal barriers and directs the fluid towards areas that benefit from rinsing and away from areas that cause discomfort.
The nasal rinse device will not block the opening of the nose or force the fluid out the opposite nostril, which means that all allergens and bacteria are properly flushed out of the nose and not pushed towards the back of the throat and into the body. As noted by a recent usage study conducted by Neosinus, the effectiveness of the product and improved overall experience for patients has resulted in medical compliance in terms of product usage near 90%. As highlighted by the global problem of medication adherence being less than 50%, healthcare providers recognize that outcomes will not improve unless usage compliance improves, so the level of compliance achieved by the Neosinus device represents a major medical step forward.
“We are truly excited to be working with US ENT Partners, who are recognized as a leading GPO for the ENT community that is focused on delivering real value, said Don Turner, Chairman and CEO of Neosinus Health. “Mostly importantly, we continue to receive extremely positive feedback from doctors and patients on the gentle and effective experience with our device, so this is truly a big win for healthcare. With allergy season coming, and ongoing concerns about upper respiratory infections from viruses that enter through the nose, the timing of this partnership could not be better.”
Keith Matheny, Chairman and CEO of US ENT, said “Our mission at US ENT Partners is to continually drive innovation and value that leads to better patient care, by partnering with the highest caliber, market leaders in the ENT space. This partnership with Neosinus Health will bring value to both our physician partners as well as their patients, by expanding access to better topical nasal rinse therapy for chronic sinus and allergy sufferers.”
Neosinus Health Inc. is a Raleigh-based drug development platform company that has commercialized a patented and configurable intranasal drug delivery platform for targeted therapy. The core platform is designed to optimize the delivery of medications to essential drug pathways and overcome physiological barriers like no other device. The company has commercialized a platform that will transform the delivery of drugs for neurological and psychiatric disorders, respiratory illnesses, viral infections, and more through strategic out-licensing partnerships and internal clinical development programs. The company is playing a leadership role in advancing a new and innovative class of brain drugs and psychedelics that will address the largest global health burden and finally deliver new therapies that have been unattainable for many decades.
About US ENT Partners
US ENT Partners is a broad, Otolaryngology-Head & Neck Surgery specific, physician office-based Group Purchasing Organization (GPO), founded by Dallas-based ENT surgeon, Dr. Keith Matheny. Otolaryngology is a very expensive medical specialty for a physician to practice, especially with recent technological advances with office balloon sinuplasty, with hearing instruments, with new diagnostics & therapeutics for Allergy and Sleep Apnea, etc. US ENT has partnered with over 30 Suppliers to bring meaningful, volume-based discounts on the purchases of these high-cost supplies to physicians who are members of this GPO, thus allowing them to remain independent & to continue to provide the highest quality, cutting-edge care to their patients.
Neosinus Health Media Contact: PR@neosinus.com
For more information on Neosinus Health: www.neosinus.com
For more information on US ENT Partners: www.usent.com
July 02, 2021
Neosinus enters into Strategic Partnership with DailyBreath to Collaborate on Improving Allergy and Asthma Management
March 30, 2021